KPIs & Operating Metrics(New)
Additions To Property And EquipmentAdjusted Income Before TaxAdjusted Income Before Tax By SegmentAssets By SegmentBreakdown Of AssetsCardiovascular/Metabolism/Other RevenueCardiovascular/Metabolism/Other Revenue AnnualConsumer RevenueContractual BoligationsCost Of Products SoldDisaggregated Revenue Mix %Disaggregated RevenuesEarnings Before Taxes On IncomeEbt By SegmentEbt By Segment AnnualEbt Margin By Segment Annual %Employee StatisticsFacilites By RegionGross Margin %Gross ProfitImmunology RevenueImmunology Revenue AnnualInfectious Diseases RevenueInfectious Diseases Revenue AnnualInnovative Medicine Revenue Breakdown AnnualInternational Sales By SegmentInterventional Solutions Revenue AnnualInventoriesLong Lived Assets By RegionMedical Devices RevenueMedical Devices Revenue AnnualMedtech Revenue Breakdown AnnualNeurosciences RevenueNeurosciences Revenue AnnualNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Oncology RevenueOncology Revenue AnnualOpex As A % Of RevenueOPEX SegregationOrthopaedics Revenue AnnualPharmaceutical Revenue BreakdownProperty And Equipment SegregationPulmonary Hypertension RevenuePulmonary Hypertension Revenue AnnualRevenue By ProductRevenue By Product %Revenue By RegionRevenue By Region %Revenue By Region (Annual)Revenue By Region (Annual) %Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %Square Footage By RegionSurgery Revenue AnnualUs Sales By SegmentVision Revenue Annual
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Johnson & Johnson (JNJ) Gross Profit (2016 - 2025)

Johnson & Johnson (JNJ) has disclosed Gross Profit for 17 consecutive years, with $16.6 billion as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 7.82% to $16.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $63.9 billion through Dec 2025, up 4.22% year-over-year, with the annual reading at $63.9 billion for FY2025, 4.22% up from the prior year.
  • Gross Profit hit $16.6 billion in Q4 2025 for Johnson & Johnson, down from $16.7 billion in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $16.7 billion in Q3 2025 to a low of $13.8 billion in Q2 2022.
  • Historically, Gross Profit has averaged $15.1 billion across 5 years, with a median of $15.0 billion in 2023.
  • Biggest five-year swings in Gross Profit: soared 33.75% in 2021 and later fell 14.07% in 2022.
  • Year by year, Gross Profit stood at $16.1 billion in 2021, then fell by 14.07% to $13.8 billion in 2022, then grew by 5.59% to $14.6 billion in 2023, then grew by 5.45% to $15.4 billion in 2024, then grew by 7.82% to $16.6 billion in 2025.
  • Business Quant data shows Gross Profit for JNJ at $16.6 billion in Q4 2025, $16.7 billion in Q3 2025, and $16.1 billion in Q2 2025.